Hsbc Holdings PLC Invests $35.42 Million in Zimmer Biomet Holdings, Inc. $ZBH

Hsbc Holdings PLC bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 413,195 shares of the medical equipment provider's stock, valued at approximately $35,417,000. Hsbc Holdings PLC owned approximately 0.22% of Zimmer Biomet at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Dodge & Cox lifted its stake in shares of Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider's stock valued at $2,113,736,000 after purchasing an additional 290,676 shares during the last quarter. Vanguard Group Inc. raised its holdings in Zimmer Biomet by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider's stock valued at $2,111,658,000 after buying an additional 192,517 shares during the period. BlackRock Inc. bought a new stake in Zimmer Biomet in the second quarter worth $1,344,282,000. State Street Corp lifted its position in Zimmer Biomet by 2.3% in the fourth quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider's stock worth $795,814,000 after buying an additional 195,214 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider's stock worth $601,204,000 after buying an additional 2,017,857 shares during the period. Institutional investors own 88.89% of the company's stock.

Analyst Ratings Changes

ZBH has been the topic of several recent analyst reports. BMO Capital Markets reissued a "market perform" rating and issued a $96.00 target price on shares of Zimmer Biomet in a research note on Thursday, August 6th. Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Royal Bank Of Canada upped their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Citigroup decreased their price objective on shares of Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating for the company in a research note on Thursday, May 28th. Finally, UBS Group restated a "buy" rating and set a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $104.42.

Zimmer Biomet Trading Down 2.0%

Shares of ZBH opened at $99.40 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $106.88. The company has a 50-day moving average of $93.63 and a 200 day moving average of $91.38. The firm has a market capitalization of $18.96 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 2.76 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Company Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source